To include your compound in the COVID-19 Resource Center, submit it here.

Integrilin eptifibatide: Phase III; marketed to treat acute coronary syndromes

MLNM began the Phase III ADVANCE MI trial in up to 6,000 heart attack patients in

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE